Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Minocycline
Drug ID BADD_D01470
Description Minocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria.[A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.[A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]
Indications and Usage Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris.[L11701,L11704,L11719] Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis.[L11716] Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms.[L11707,L11710,L11713] These include rickettsiae, _Mycoplasma pneumoniae_, _Chlamydia trachomatis_, _Chlamydophila psittaci_, _Chlamydia trachomatis_, _Ureaplasma urealyticum_, _Borrelia recurrentis_, _Haemophilus ducreyi_, _Yersinia pestis_, _Francisella tularensis_, _Vibrio cholerae_, _Campylobacter fetus_, _Brucella_ species, _Bartonella bacilliformis_, _Klebsiella granulomatis_, _Escherichia coli_, _Enterobacter aerogenes_, _Shigella_ species, _Acinetobacter_ species, _Haemophilus influenzae_, and _Kelbsiella_ species.[L11710]
Marketing Status approved; investigational
ATC Code A01AB23; D10AF07; J01AA08
DrugBank ID DB01017
KEGG ID D05045
MeSH ID D008911
PubChem ID 54675783
TTD Drug ID D08LTU
NDC Product Code 49884-512; 69489-212; 72356-101; 49884-513; 42291-589; 69489-201; 72356-103; 49884-511; 42291-591
UNII FYY3R43WGO
Synonyms Minocycline | Minox 50 | Aknemin | Aknin-Mino | Aknin Mino | Aknosan | Mynocine | Apo-Minocycline | Apo Minocycline | Arestin | Blemix | Cyclomin | Cyclops | Dentomycin | Dynacin | Icht-Oral | Icht Oral | Klinomycin | Lederderm | Mestacine | Minakne | Mino-Wolff | Mino Wolff | Minocin | Minocin MR | Minoclir | Minocycline Hydrochloride | Hydrochloride, Minocycline | Minocycline Monohydrochloride | Monohydrochloride, Minocycline | Minocycline, (4R-(4 alpha,4a beta,5a beta,12a beta))-Isomer | Minolis | Minomycin | Minoplus | Minotab | Akamin | Akne-Puren | Akne Puren
Chemical Information
Molecular Formula C23H27N3O7
CAS Registry Number 10118-90-8
SMILES CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Treatment failure08.06.01.0170.001759%Not Available
Liver injury12.01.17.012; 09.01.07.0220.000177%Not Available
Gingival erythema07.09.13.0060.000602%Not Available
Type 1 diabetes mellitus05.06.01.010; 14.06.01.010; 10.04.08.0070.000944%Not Available
Skin mass23.07.04.0140.000236%Not Available
Cholestatic liver injury09.01.07.0160.000118%Not Available
Occipital neuralgia17.14.01.013--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000980%
Brain stem stroke24.04.06.024; 17.08.01.0330.000413%Not Available
Acute kidney injury20.01.03.0160.002302%
Allergic hepatitis10.01.03.038; 09.01.07.0270.000118%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.005903%Not Available
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.009268%Not Available
Candida infection11.03.03.021--
Noninfective gingivitis07.09.13.0160.000401%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.001830%
Antiphospholipid syndrome24.01.01.029; 10.04.01.009; 18.02.04.002; 01.01.02.0160.000295%Not Available
Catabolic state14.11.01.0340.000118%Not Available
Dermatitis exfoliative generalised23.03.07.002; 10.01.01.0290.000295%Not Available
Lateral medullary syndrome24.04.06.038; 17.08.01.0550.000236%Not Available
Mononeuropathy multiplex17.09.02.0120.001535%Not Available
Normal pressure hydrocephalus17.07.01.0020.000649%Not Available
Post inflammatory pigmentation change23.05.03.0020.000177%Not Available
Renal arteritis24.12.02.007; 20.01.07.0130.000177%Not Available
Symblepharon06.06.02.0120.000295%Not Available
Testicular infarction24.04.12.003; 21.13.01.0090.000531%Not Available
Thyroiditis acute05.02.04.0040.000885%Not Available
Anti-neutrophil cytoplasmic antibody positive vasculitis24.12.04.002; 10.02.02.0230.001535%Not Available
Eosinophilic pneumonia chronic01.02.04.017; 22.01.01.0200.000236%Not Available
Aortic valve disease02.07.03.0020.000236%
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene